Turkish Abstract Abstract PDF Similar Articles Mail to Author

¹Atatürk Eğitim Araştırma Hastanesi 1. Göz Kliniği, Ankara, Asist. Dr.
²Atatürk Eğitim Araştırma Hastanesi 1. Göz Kliniği, Ankara, Uzm. Dr.
³Atatürk Eğitim Araştırma Hastanesi 1. Göz Kliniği, Ankara, Doç. Dr.
⁴Atatürk Eğitim Araştırma Hastanesi 1. Göz Kliniği, Ankara, Prof. Dr. Purpose: Evaluating changes in intraocular pressure and ocular pulse amplitude in eyes with intravitreal bevacizumab injection.
Materials and Methods: 18 eyes of 17 patients with intravitreal bevacizumab injection were included in the study. Intraocular pressure (IOP) (by GAT and by PDCT) and ocular pulse amplitude (OPA) (by PDCT) were measured before and after the intravitreal injection.
Results: The IOP before injection was 15.25±2.91 mmHg while 30 minutes and 1 week after the injection the IOP was 16.35±3.32 mmHg and 14.65±5.11 mmHg respectively by GAT. The IOP before injection was 18.17±1.11 mmHg while 30 minutes and 1 week after the injection the IOP was 19.94±1.26 mmHg and 17.25±3.23 mmHg respectively by PDCT. The IOP values before the injection were not significantly different from the measurements both 30 minutes and 1 week after the injection by both of the methods (The p values for the measurements 30 minutes and one week after the injection by GAT were 0.180 and 0.550 respectively; and by PDCT they were 0.169 and 0,379 respectively). The OPA before the injection was 2.74±1.01 mmHg whereas 30 minutes and 1 week after the injection the OPA values were 3.05±1.20 mmHg and 2.58±1.12 mmHg respectively. The OPA measurements 30 minutes after injection were significantly increased according to preinjection values (p=0.035).
Conclusion: Early changes in IOP after intravitreal bevacizumab injection were not noted by GAT and PDCT. The OPA by PDCT was significantly increased 30 minutes after the injection. This increase in OPA may be caused by early effects of bevacizumab on choroidal blood flow. However we think that we need future studies providing the nomograms of this new method for measurement of OPA to evaluate the clinical significance of measurements. Keywords : Bevacizumab, IOP, GAT, Ocular Pulse Amplitude, Pascal Dynamic Contour Tonometer